Takeda eosinophilic esophagitis asset resubmission accepted by FDA

Hailshadow/iStock via Getty Images

• The US FDA has accepted resubmission of a New Drug Application for Takeda Pharmaceutical's (NYSE:TAK) eosinophilic esophagitis candidate TAK-721 (budesonide oral suspension).
• The FDA action date is the first half of 2024.
• In December 2021, Takeda (TAK) received a Complete Response Letter from the agency on the asset suggesting it conduct an additional trial.

More on Takeda Pharmaceutical

• Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
• ImmunoGen inks deal with Takeda for cancer drug Elahere
• Takeda pulls marketing application for dengue vaccine in the U.S.
• Seeking Alpha’s Quant Rating on Takeda Pharmaceutical